Janssen P A
Janssen Pharmaceutica N.V., Beerse, Belgium.
Pharmacopsychiatry. 1988 Jan;21(1):33-7. doi: 10.1055/s-2007-1014643.
The involvement of central serotonergic mechanisms in the organisation of human sleep has been confirmed in several single and multiple-dose clinico-pharmacological studies with the specific serotonin-S2-antagonist ritanserin. The pronounced thymosthenic effect observed with this compound in patients suffering from dysthymia, generalized anxiety disorder and negative symptoms of schizophrenia can possibly be attributed to a restoration of the energetic function during the night as a consequence of a dramatic increase in slow wave sleep during treatment with ritanserin.
在多项单剂量和多剂量临床药理学研究中，使用特异性血清素-S2拮抗剂利坦色林已证实中枢血清素能机制参与人类睡眠的组织。在患有心境恶劣障碍、广泛性焦虑症和精神分裂症阴性症状的患者中，使用该化合物观察到的明显的精神振奋作用，可能归因于在利坦色林治疗期间慢波睡眠急剧增加，从而恢复了夜间的精力功能。
